Several PHRI researchers presented at the International Stroke Congress (ISC) 2025, held in Los Angeles, California, from February 5-7, 2025.
Senior Scientist Ashkan Shoamanesh presented on
- “Emerging Antithrombotic Options for Stroke Prevention”
- “Antithrombotic Treatment in ICH: Perspectives from Vascular Neurology”
- “Pro: Andexanet Alfa is Preferred over PCC for Reversal of FXa Inhibitor-Associated ICH”
He also presented a late-breaking science poster on a substudy of the ANNEXa-I: “Association of Biomarkers with risk of Hematoma Expansion and Arterial Thromboembolic Events in Acute Factor Xa Inhibitor-Associated Intracerebral Hemorrhage.”
An interesting debate on pros (by @Ash_Shoamanesh) and cons (by @ShadiYaghi2) of Andexanet!
36%RRR hematoma expansion
More ischemic events
Neutral effect on 30-day mRS/mortality (though short follow-up and underpowered for these outcomes)
Expensive (see 1st slide) #ISC25 pic.twitter.com/5STPDJajpy— Pargol balali (@PargolBalali) February 5, 2025
Scientist Raed Joundi delivered two presentations:
- “Designing post-stroke cognitive trials- populations, endpoints, cognitive measurements, targets.”
- “Long-term temporal trends in post-stroke dementia, 2002-2022: A population-wide cohort study”
Scientist Mike Sharma moderated a session on “Post-stroke Cognitive Impairment and Dementia: New Insights, Challenges and Opportunities,” where he and Joundi shared insights from the PROSPECT trial. Sharma also presented a late-breaking science poster on the ANNEXA-I trial:
“Restarting Anticoagulation in FXa Inhibitor-Associated Intracerebral Hemorrhage Treated with Andexanet Reduces Thrombotic Events.”
Scientist Aristeidis Katsanos presented on the use of anti-inflammatory medications for stroke prevention and discussed the CoVasc-ICH trial. This trial aims to evaluate the feasibility, safety, and potential efficacy of colchicine in reducing thromboembolic events and mitigating secondary inflammatory brain injury in patients with acute intracerebral hemorrhage (ICH) and systemic atherosclerosis, without increasing the risk of re-bleeding. He also delivered a presentation on “Management Decisions Surrounding Antithrombotic Treatment in Patients with ICH.”
